<DOC>
	<DOCNO>NCT01381328</DOCNO>
	<brief_summary>The purpose study correlate different pattern resistance mutation observe vivo patient fail RAL treatment fold-change resistance determine phenotypic assay .</brief_summary>
	<brief_title>GePheRal : Clinical Validation Genotypic Diagnosis Hiv-1 Resistance Raltegravir Parallel Analysis Genotype Phenotype Profiles Resistance</brief_title>
	<detailed_description>The secondary objective , follow : - establish standardise genotypic assay HIV-1 pol gene region ( region interest , sensitivity , mutation involve primary compensatory change , role polymorphism present baseline ) . - reach consensus algorithm interpretation house ex-vivo genotypic evaluation . - assess genetic change RAL-failing patient continuous drug pressure drug discontinuation ( dynamic reversion resistance mutation ) . - evaluate RAL resistant HIV-1 variant change replication capacity ( RC ) ( baseline vs. following-timepoints ) . - evaluate immunological virological trend associate raltegravir-regimen failure .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Adult ( least 18 year age ) treatmentexperienced , HIVinfected subject either sex race , fail RALcontaining regimen enrol study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>HIV-1 infect patient</keyword>
	<keyword>RALTEGRAVIR regimen</keyword>
	<keyword>genotypic evaluation</keyword>
	<keyword>phenotypic evaluation</keyword>
</DOC>